Please login to the form below

Not currently logged in
Email:
Password:

Pfizer promotes Olivier Brandicourt to emerging markets president

Will also head established products business units following David Simmons’ departure

Olivier Brandicourt - PfizerPfizer has promoted president and general manager of the pharma company's primary care business unit, Dr Olivier Brandicourt, to president and general manager of its emerging markets and established products business units.

Taking over his new position on June 1, he replaces the departing David Simmons who is leaving to become chair and CEO of contract research organisation PPD.

Brandicourt's previous experience at Pfizer includes country and regional management roles in Latin America, Europe, Canada, the UK and the US, and he is also a member of the company's executive leadership team.

“Olivier is ideally suited to take on this new role,” said Ian Read, Pfizer's chair and CEO. “He has more than 20 years of global experience in the pharmaceutical industry.

“Olivier is both a physician and proven business leader who understands the many challenges of today's changing industry and healthcare landscape.”

During his time as a practicing physician, Dr Brandicourt specialised in infectious diseases, and spent two years in the Congo.He also spent four years in West and central Africa working in malaria research as part of an eight-year spell with the tropical disease institute in Paris.

Replacing Dr Brandicourt as president and general manager of the pharma company's primary care business is John Young, who is currently regional president of Europe and Canada for Pfizer.

Young has spent 25 years with the firm, holding several senior commercial roles in Australia/New Zealand and in the UK.

“John has a deep understanding of the primary care landscape and will be a strong leader for this significant part of our business,” said CEO Read.

24th May 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics